Please assess the completion status of the following clinical trial:

Trial Title: Comparison of RPL554 With Placebo and Salbutamol in Asthmatic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Provided written informed consent~* Males agree not to donate sperm and either be abstinent or use adequate contraception. Females to be post-menopausal or surgically sterile~* Non-smoker or ex-smoker \>6 months~* Diagnosed asthma for at least 6 months~* Pre-bronchodilator FEV1 ≥60% and ≤90% of predicted normal value and ≥1.5 L at screening~* Increase in FEV1 of 15% within 30 minutes after a 2.5mg dose of nebulised salbutamol~* Systolic blood pressure 90 to 145 mmHg, diastolic blood pressure 50 to 90 mmHg and heart rate 45 to 80 beats per minute (bpm) after resting for 5 minutes in a supine position (average from two measurements)~* Capable of withdrawing from LABAs, LAMAs and SAMAs before screening and during study and SABAs before screening and for 8 hours before each dose~Exclusion Criteria:~* Asthma exacerbation in the last 3 months~* Any prior life threatening episode of asthma (intensive care admission)~* Any clinically significant disease or disorder or clinically relevant screening result~* QTcF interval \>450 ms or QT interval \>500 ms or other abnormality in ECG~* History of ischemic heart disease or heart failure. History of recurrent or current clinically significant arrhythmia or ECG abnormality as judged by the investigator~* Treatment with systemic glucocorticosteroids within 30 days before screening~* A suspected/manifested infection according to WHO risk classification 2, 3 or 4

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Single dose of nebulised placebo solution
- RPL554 Dose 1 (Type: EXPERIMENTAL): 0.4 mg single dose nebulised RPL554
- RPL554 Dose 2 (Type: EXPERIMENTAL): 1.5 mg single dose nebulised RPL554
- RPL554 Dose 3 (Type: EXPERIMENTAL): 6 mg single dose nebulised RPL554
- RPL554 Dose 4 (Type: EXPERIMENTAL): 24 mg single dose nebulised RPL554
- Salbutamol Dose 1 (Type: ACTIVE_COMPARATOR): 2.5 mg single dose nebulised salbutamol
- Salbutamol Dose 2 (Type: ACTIVE_COMPARATOR): 7.5 mg single dose nebulised salbutamol

Based on this trial design, predict the completion outcome and termination type (if applicable).